FINRA halted trading in MMTLP under FINRA Rule 6440(a)(3) as an extraordinary event halt. Under the corporate action schedule announced by Meta Materials Inc., the Series A Preferred shares were to be canceled and exchanged for shares of Next Bridge Hydrocarbons, Inc., an unlisted private company.
Because standard equity settlement in the United States requires two business days (T+2 under SEC Rule 15c6-1), trades executed on Friday, December 9 would not settle until Tuesday, December 13—after the corporate record date of December 12, 2022. Consequently, purchasers on December 9 would have no legal entitlement to receive the Next Bridge shares, and sellers would have no ability to deliver private unlisted stock. FINRA acted to prevent widespread settlement failures and clearing gridlock.
No. FINRA's regulatory mandate is to maintain orderly markets and ensure that trades executed on public quotation venues can clear and settle in accordance with federal law. FINRA does not intervene to protect short sellers or prevent short squeezes.
In response to widespread claims on social media of hundreds of millions of “naked” or counterfeit short positions, FINRA collected and analyzed Electronic Blue Sheet (EBS) data from all clearing firms and broker-dealers holding positions in MMTLP.
As published in FINRA's Supplemental FAQ on November 6, 2023, the total aggregate short position in MMTLP as of December 12, 2022 was approximately 2.65 million shares (~2,651,691 shares), representing approximately 1.6% of the 165,523,363 total outstanding Series A Preferred shares.
No. In regulatory responses and Congressional inquiries, FINRA confirmed that it did not process or approve a Form 211 application under FINRA Rule 6432 for MMTLP.
Instead, broker-dealers quoted and executed trades in MMTLP pursuant to the unsolicited customer order exception under SEC Rule 15c2-11(f)(2). Ticker symbol MMTLP was assigned by FINRA Market Operations strictly as an administrative symbol to allow trades to be processed and reported for price transparency to the OTC Reporting Facility (ORF).